Your browser does not support iframes.
Investors locked in profits on Arena Pharmaceuticals Inc. (Nasdaq: ARNA) whose stock price climbed the past week in anticipation of regulatory approval of its obesity treatment Lorcaserin. The stock price fell $1.68 to $10.00.